Introduction
============

Paclitaxel (Taxol), a classic microtubule-targeting agent, is one of the most useful antineoplastic agents ([@B28]; [@B37]; [@B39]). It binds to tubulin ([@B42]). This binding results in a cascade of disruptions ultimately ending in cancer cell death. First, this binding changes the dynamic equilibrium between assembly and disassembly of microtubules, which actively prolongs mitotic arrest ([@B41]). It also disrupts the cytoskeletal framework that is necessary for tumor cell replication and metastatic spread ([@B23]; [@B46]), and this disruption subsequently triggers cancer cell death not only in mitotic arrest state, but also after mitotic slippage to an abnormal G1 ([@B47]). Taxol has been commonly prescribed to treat a variety of tumors, particularly ovarian and breast cancer ([@B31]; [@B14]; [@B26]; [@B4]; [@B22]).

In addition to its advantages, Taxol also, unfortunately, induces some cytotoxic effects, such as neurotoxicity, hypersensitivity reactions, hematologic toxicity, cardiac disturbances, and gastrointestinal tract symptoms. These side effects have severely limited its optimal clinical application as an anti-cancer agent ([@B16]). Some compounds have been reported to reduce its cytotoxicity ([@B36]). For example, *Vernonia amygdalina* (Bitter Leaf Plant; Asteraceae) has been reported to improve the anticancer effects of Taxol against breast cancer, while reducing harmful side effects ([@B11]). Mito VitE was reported to have the ability to abrogate the mitochondrial function and glutathione in DRG cells affected by Taxol, without decreasing cancer cell cytotoxicity ([@B24]). Fibrates can also be used to reduce the vascular endothelial dysfunction induced by Taxol ([@B38]). Other reagents and methods such as those involving nanoparticles, bevacizumab ([@B25]) and doxorubicin ([@B34]) have also been tested with Taxol to reduce its cytotoxicity or improve its anticancer effect ([@B32]). Unfortunately, most of agents themselves are also chemotherapeutic and have some safety concerns, e.g., cardiac toxicity and neutropenia ([@B30]; [@B44]). Furthermore, the underlying mechanism has not been studied extensively.

Chinese medicines in combination with paclitaxel was reported to significantly decrease the risk in 729 patients with advanced breast cancer in the clinic ([@B18]). In another clinical trial, which used 314 patients to evaluate the effect of Traditional Chinese Medicine (TCM) as a combination medication with adjuvant chemotherapy, Radix Astragali was used to strengthen the healthy qi and eliminate pathogenic factors for patients. The skeleton component of the Chinese Medicine formula used in this clinical trial is Radix Astragali which is often used as an edible tonic herb for improving the immune system and strengthening the physique ([@B12]). Polysaccharides are believed to be the major active ingredients in Radix Astragali ([@B35]), and have demonstrated its immune-modulatory, anti-tumor ([@B13]), anti-virus ([@B7]), and inflammatory properties ([@B1]). RAP, a major polysaccharide purified from Radix Astragali in our previous work, has been studied in terms of its immune-modulatory and anti-tumor properties. Our results showed that RAP affected the cytokine profile of unstimulated human peripheral blood mononuclear cell (PBMC). RAP was able to stimulate the expression of IL-1 and TNF-α, which are important in bacterial immune responses. It can also induce the expression of IL-10, IL-12, and GM-CSF. The fact that these cytokines are related to monocytes suggested that RAP is an activator of monocytes ([@B43]). Further studies have revealed that TLR 4 is a receptor of RAP and can mediate its immune activities, since RAP activated TLR 4 related MAPKs, including phosphorylated ERK, phosphorylated JNK, and phosphorylated p38, and induced translocation of NF-κB as well as degradation of IκB ([@B40]).

Our preliminary study found that RAP preserved RAW 264.7 cells in normal cell activity and cell profile from the impact of Taxol within 72 h using a live cell image system (data not shown). The current study was used to confirm the protective effect of RAP to Taxol and explore the underlying mechanism in terms of cell cycle arrest and apoptosis.

Materials and Methods {#s1}
=====================

Reagents
--------

Paclitaxel (Taxol) was purchased from Sigma-Aldrich, Inc. (St. Louis, MO, United States). Phospho-Histone H~2~A. X, PARP, Bcl-Xl, Mcl-1, Chk 1, and p53 antibody were provided by Cell Signaling (Beverly, MA, United States). The antibody of p21 was purchased from Santa Cruz Biotechnology (Santa Cruz, CA, United States).

Cell Lines and Mice
-------------------

4T1 mouse breast cancer cell lines and RAW 264.7 murine macrophage cell lines were originally obtained from the American Tissue Culture Collection. Cells were grown in a 35 mm dish at 37°C in a humidified atmosphere of 5% CO~2~ and were maintained as monolayer cultures in Dulbecco's minimal essential medium supplemented with 10% fetal bovine serum, 100 U/mL penicillin and 100 μg/mL streptomycin.

BALB/C mice, aged 6--8 weeks (18--20 g) were purchased from the Chinese University of Hong Kong and maintained under clean conditions in an animal room in Hong Kong Baptist University. The animals had free access to food and water in animal cages that were maintained in a pathogen-free environment (24 ± 1°C, humidity of 55 ± 5%) with a 12/12 light cycle.

RAP Preparation
---------------

The roots of *Astragalus membranaceus* were purchased from a herbal store in Hong Kong and identified by Dr. Chun-Feng Qiao. The voucher specimens are deposited at the Institute of Chinese Medicine, the Chinese University of Hong Kong, with voucher specimen number 2010--3268 ([@B43]). The isolation and purification procedure was performed according to the previous study ([@B43]). Briefly, the air-dried Radix Astragali was powdered and extracted twice with boiling water. The solution was filtered, combined, and concentrated. The solution was precipitated with absolute ethanol. The precipitate was resolved again in water and deproteinated. The water solution was then dialyzed. Finally, the retentate was lyophilized. The product was dissolved in distilled water again and separated with a Hiload 26/60 Superdex-200 column that was eluted with water. Fractions were collected, dialyzed, and finally lyophilized to obtain RAP. The RAP used in this study was not contaminated with endotoxin.

RAP is a water soluble polysaccharide ([@B43]). Its structure was elucidated by monosaccharide composition, partial acid hydrolysis and methylation analysis, and further confirmed by FT-IR, GC--MS and ^1^H and ^13^C NMR spectra, SEM and AFM microscopy. Its average molecular weight was 1334 kDa and composed of Rha, Ara, Glc, Gal, and GalA in a molar ratio of 0.03:1.00:0.27:0.36:0.30. The backbone of RAP consisted of 1,2,4-linked Rhap, α-1,4-linked Glcp, α-1,4-linked GalAp6Me, β-1,3,6-linked Galp, with it branched at O-4 of the 1,2,4-linked Rhap and O-3 or O-4 of β-1,3,6-linked Galp. The side chains mainly consisted of α-T-Araf and α-1,5-linked Araf with O-3 as branching points, having trace Glc and Gal. The terminal residues were T-linked Araf, T-linked Glcp, and T-linked Galp.

Mice Mammary Tumor Model Establishment and Treatment
----------------------------------------------------

All animal operations were performed according to the guidelines of the Animal Experimentation Ethics Committee of Hong Kong. The mice were housed in groups of four to five animals per cage for 1 week before the experiment. To establish the tumor model, well cultured 4T1 cells (4 × 10^5^/each mouse) were collected and washed 3 times before re-suspended in 0.2 ml phosphate buffered saline (PBS). The cells were subcutaneously (s. c.) inoculated into the mammary fat pad of each mouse. The tumor-bearing mice were randomly divided into four groups (*n* = 10): Control group (dH~2~O, oral gavage), RAP group (40 mg/kg/day/mouse, oral gavage), Taxol group (20 mg/kg/week/mouse, intraperitoneal injection) and RAP+Taxol group (RAP 40 mg/kg/day/mouse+Taxol 20 mg/kg/week/mouse). In groups receiving RAP, RAP was initiated 10 days before cancer cell implantation and was continued every day thereafter. During and after the treatment lasting for 6 weeks, deaths of mice were recorded every day, and survival rate was monitored until the end of the period.

MTT Assay
---------

4T1 and RAW 264.7 Cells were plated in 96-well plates at 5 × 10^4^ cells (100 μL) per well. The next day, cells were treated with a different concentration of RAP (12.5, 25, 50, 100 μg/mL) in three replicates for 24 h. Following incubation, MTT solution (5 mg/mL in PBS) was added to each well and the plates were incubated at 37°C for another 4 h. The medium was then discarded and DMSO was added to dissolve the formazan crystals. The absorbance of each sample was read at 490 nm using a Benchmark Plus microplate reader (Bio-Rad, Richmond, CA, United States).

Cells Co-culture Model
----------------------

The effect of RAP with/without Taxol on the cell viability of 4T1 cells and RAW 264.7 cells in a co-culture model was measured by MTT assay. As [Figure 2A](#F2){ref-type="fig"} showed, 4T1 cells (2 × 10^5^) were first planted on the 24-well plates, then the RAW 264.7 cells (2 × 10^4^) were seeded on the collagen-coated polycarbonate transwell membrane (corning, 6.5 mm diameter, 3.0 μm pore size), and were put inside the wells of 24-well plates (cultured together with 4T1 cells). 4T1 and RAW 264.7 cells alone were added to 24-well plates as a control. Culture medium (0.1 mL within the insert, 0.6 mL in the outer well) was replaced after 24 h, then cells were incubated with different concentrations of RAP (12.5--100 μg/mL) with/without Taxol (10 μM) for 24 h. Following incubation, MTT assay was used to measure the cell proliferation.

Cell Cycle and Apoptosis Analysis by Flow Cytometry
---------------------------------------------------

The cellular DNA content of treated RAW 264.7 cells was determined by staining cells with PI and measuring on a flow cytometer. Well cultured RAW 264.7 cells (2 × 10^6^/well) were seeded in a 6-well plate and then treated with RAP (50 μg/mL) with/without Taxol (10 μM). After 24 h, cells were collected and washed twice in PBS, followed by fixation in 70% ethanol on ice for 2 h. Cells were then re-suspended in 0.45 mL PBS and 25 μL of 2 mg/mL RNase A at 37°C for 15 min, and finally stained with 20 μL of 1 mg/mL PI for 30 min, before detection with a flow cytometer.

Apoptotic cells were labeled using an Annexin V-FITC/ PI apoptosis detection kit (Sigma, United States) and then also detected using the Flow cytometer. Briefly, cells were separated into 4 groups as before, after 24 h, cells were collected and washed twice with cold PBS and re-suspended in 500 μL buffer, then measured with a flow cytometer.

Hoechst 33342 Staining
----------------------

Replicate cultures of 2 × 10^5^ RAW 274.7 cells per well were plated in 24-well plates. RAP (50 μg/mL) with/without Taxol (10 μM) were added to cells after 24 h. After treatment for 24 h, cells were incubated with 5 μL of Hoechst 33342 solution (Sigma, United States) per well at 37°C for 10 min, followed by observation under a fluorescence microscope. Fluorescence was observed in the nuclei and multiple nuclei could be detected at higher magnifications.

Western Blot
------------

Replicate cultures of 1 × 10^6^ RAW 274.7 cells per well were seeded in 6-well plates, then treated with RAP (50 μg/mL) with/ without Taxol (10 μM) for 24 h. After that, cells were washed twice with phosphate buffered saline and harvested in cold lysis buffer containing protease inhibitors or phosphatase inhibitors. Cell lysates were collected from culture plates, and protein were collected by centrifugation. The concentrations of proteins were determined by a BCA protein assay (Pierce Biotechnology, Rockford, IL, United States). The total protein was boiled in 4× loading buffer (Bio-Rad, United States) for 10 min at 100°C, then loaded into various concentrations of Tris--HCl-Polyacrylamide gels according to its molecular properties (from 6 to 12%), and transferred electrophoretically to an Immobilon-P membrane (Millipore Corporation, Billerica, MA, United States). Membranes were incubated with primary antibodies and appropriate horseradish peroxidase-labeled secondary antibodies. Membranes were additionally probed with an antibody against β-actin (Cell Signaling) to normalize the loading of proteins among samples. In the last step, secondary antibodies were detected by chemiluminescent agents (Pierce Biotechnology).

Statistical Analysis
--------------------

All data were expressed as mean ± SD/SEM. Statistical analysis was performed using one way ANOVA, two way ANOVA and t tests, with *P*-values (P) \< 0.05 regarded as statistically significant. Each experiment was repeated at least three times, and each data point represents the mean of at least three parallel samples. All calculations were performed using Prism 5 software.

Results
=======

RAP Increased the Survival Rate in Mammary Tumor Model Mice
-----------------------------------------------------------

Seven days after BALB/c mice were inoculated with 4T1 mouse breast cancer cells, the tumor model was established successfully. As shown in [Figure 1](#F1){ref-type="fig"}, the control group of mice began to die on day 30 post tumor inoculation, whereas RAP, Taxol and RAP+Taxol treated groups did not begin to die until day 35, 50, and 52, respectively. By day 50, all of the control group mice had died. In contrast, the survival rates in the treated groups were still 50--100%. Mice in the RAP+Taxol combination group were surviving at a rate of 25% when the mice in the RAP or Taxol alone groups had all died. The data was analyzed using a Log-rank Test. Compared with control group, the RAP group, Taxol group and RAP+Taxol group showed significant differences (*p* \< 0.0001). Compared with Taxol group, RAP+Taxol group demonstrated a significant difference (*p* \< 0.05). As for tumor diameter and body weight, compared with Taxol group, RAP+Taxol group had no significant difference ([Supplementary Figure S1](#SM1){ref-type="supplementary-material"}). These observations indicated that RAP might not be able to affect Taxol's efficacy to cancer cells *in vivo*, while the combined treatment of RAP and Taxol generated synergism in term of improving survival rate than either individual therapy.

![Long time survival of 4T1 breast tumor-bearing mice treated with RAP with/without Taxol.](fphar-09-01580-g001){#F1}

RAP Reduced the Taxol-Induced Cytotoxicity Without Affecting Its Anti-tumor Efficacy
------------------------------------------------------------------------------------

We assumed that the ability of RAP to help Taxol in fighting tumor cells were due to its capacity to protect the immune cells but not the direct toxicity effect to the tumor cell itself. In order to test this hypothesis, RAP's effect on the proliferation of 4T1 cells and RAW 264.7 cells was detected. Because cancer cells and immune cells might affect each other under real situations, RAP's effect on 4T1+RAW 264.7 cells was also examined in an *in vitro* co-culture model. In all three cell experiments, cells were treated with different doses of RAP from 12.5--100 μg/mL with/ without Taxol (10 μM) for 24 h *in vitro*. As shown in [Figure 2B](#F2){ref-type="fig"}, RAP didn't induce the proliferation of 4T1 cells or RAW 264.7 cells directly. However, in the co-culture model ([Figure 2C--E](#F2){ref-type="fig"}), RAP suppressed the growth of 4T1 cells but exhibited no effect on RAW 264.7 cells. As we reported previously, RAP treatment could induce RAW 264.7 cell's inhibition against 4T1 cells in a dose-dependent manner. Of interest, RAP did not disturb the Taxol's cytotoxic effect against 4T1 cells but exhibited protection to taxol-treated RAW 264.7 cells. In other words, RAP selectively protected RAW 264.7 cells from the toxicity of Taxol without reducing Taxol's toxic effect toward cancer cells. This conclusion was supported by the results of an apoptosis assay in co-culture model ([Figure 2C](#F2){ref-type="fig"}).

![Effects of RAP with/without Taxol on 4T1 and RAW 264.7 cells. **(A)** 4T1 and RAW 264.7 cells co-culture model; **(B)** 4T1 and RAW 264.7 cells were not stimulated by RAP directly; **(C)** Apoptosis of 4T1 cells in co-culture system induced by RAP (50 μg/mL); **(D)** Proliferation of 4T1 and **(E)** RAW 264.7 cells in co-culture model treated by RAP with/ without Taxol. Data are presented as mean ± SD. Compared with the control group. ^∗^*p* \< 0.05, ^∗∗^*p* \< 0.01, ^∗∗∗^*p* \< 0.001.](fphar-09-01580-g002){#F2}

RAP Attenuated G2/M Cell Cycle Arrest of RAW 264.7 Cells Induced by Taxol
-------------------------------------------------------------------------

To investigate whether the cell cycle arrest of RAW 264.7 cells could be induced by RAP with/without Taxol, the cell cycle percentage of treated RAW 264.7 cells were detected primarily by flow cytometry analysis after PI staining. As shown in [Figure 3A,B](#F3){ref-type="fig"}, after RAW 264.7 cells were treated with RAP (50 μg/mL) with/ without Taxol (10 μM) for 24 h, changes appeared in the percentage of RAW264.7 cells at the G0-G1, S, and G2/M phases. In Taxol alone and RAP+Taxol groups, the percentage of cells at the G0-G1 phases decreased from 86 to 18% and 22%, respectively. However, cells in the G2/M phase increased from 5 to 83% and 48%. For S phase, the cell percentage only changed slightly. The results suggested that Taxol arrested the cell cycle mainly at the G2/M phase. RAP alone had no significant effect on cell cycle, but it obviously disturbed the G2/M phase arrest effect of Taxol when added together with it.

![G2/M cell cycle arrest and related proteins of RAW 264.7 cells treated by RAP (50 μg/mL) with/without Taxol (10 μM). **(A)** Diagram of cell cycle analysis in RAW 264.7 cells by flow cytometry; **(B)** Statistical analysis of G0-G1, S, and G2/M populations in RAW 264.7 cells; **(C)** Western blotting analysis of the level of phosphorylation of Chk1 (MW: 56 kDa), p53 (MW: 53 kDa), and p21 (MW: 21 kDa) protein expression; **(D)** Quantitative analysis of Chk 1, p53, and p21 (^∗^*p* \< 0.05 compared with Taxol alone group).](fphar-09-01580-g003){#F3}

Signals from the transducer to effector kinases are forwarded by mediator proteins such as Chk1, a Ser/Thr protein kinase which controls the G2/M phase transition in response to DNA damage. p53 (a tumor suppressor) activates p21 (a cyclin-dependent kinase inhibitor, which represents a major target of p53 activity), both of which have also been well established as critical mediators of cellular responses to DNA damage, apoptosis and cell cycle arrest ([@B2]; [@B45]; [@B47]). Therefore, we focused our attention on these checkpoint-related proteins. As illustrated in [Figure 3C,D](#F3){ref-type="fig"}, Taxol promoted the protein expressions of Chk 1, p53 and p21, while RAP reversed these changes.

RAP Suppressed the Apoptosis of RAW 264.7 Cells Exposed to Taxol
----------------------------------------------------------------

Apoptosis in the RAW 264.7 cells treated with RAP and with/without Taxol for 24 h were measured using flow cytometry. As shown in [Figure 4A](#F4){ref-type="fig"}, in cells treated with RAP alone, only small percentages (2.39%) of cells underwent apoptosis, while in cells treated with Taxol, the percentage of apoptotic and necrotic cells (expressed as Annexin V positive/ PI negative and Annexin V/PI positive cells) increased to 67.11%. But this effect of Taxol was blocked by RAP as demonstrated by the RAP+ Taxol group, in which the percentage of these cells fell to 44.93%. The percentage of apoptotic cells of RAW 264.7 cell which induced by RAP with/without Taxol is directly compared in [Figure 4B](#F4){ref-type="fig"}. The protective effect of different dosages of RAP can also be detected using flow cytometry. Compared with Taxol group, RAP (10--100 μg/mL)+Taxol groups had significant protective effect to RAW 264.7 cells, while there were no significant differences between different RAP dosage groups ([Supplementary Figure S2](#SM1){ref-type="supplementary-material"}). The nuclear damages were observed by Hoechst staining in control and RAP with/ without Taxol groups. The typical condensation and fragmentation of the nuclei's were easy to be observed in Taxol group, while disappearing in RAP combine Taxol group ([Figure 4C,D](#F4){ref-type="fig"}). The results shown here demonstrated that Taxol is toxic to RAW 264.7 cells, but RAP can protect them from this toxicity.

![Apoptosis of RAW 264.7 cells treated by RAP (50 μg/mL) with/without Taxol (10 μM). **(A)** Apoptotic effect of RAP with/without Taxol on RAW 264.7 cells detected by flow cytometry; **(B)** Statistical analysis of apoptotic effect of RAP with/without Taxol detected by flow cytometry; **(C)** Apoptosis that assessed by Hoechst 33342 staining: red arrow showed some of the typical "apoptotic bodies." **(D)** Statistical analysis of apoptotic effect of RAP with/without Taxol detected by Hoechst staining; **(E)** Western blotting analysis of Phospho-Histone H2A. X (MW: 15 kDa), PARP (full length, MW: 116 kDa), Bcl-Xl (MW: 30 kDa) and Mcl-1 (MW: 35 kDa); **(F)** Quantitative analysis of Phospho-Histone H2A. X, PARP, Bcl-Xl, and Mcl-1 (^∗^*p* \< 0.05 compared with Taxol alone group). Data are presented as mean ± SD. Compared with the control group. ^∗^*p* \< 0.05, ^∗∗^*p* \< 0.01, and ^∗∗∗^*p* \< 0.001.](fphar-09-01580-g004){#F4}

It is well established that Taxol-mediated DNA damage triggers apoptosis. In order to find the related probable mechanism, Phospho-Histone H~2~A, and PARP (both are DNA damage markers) and Bcl-Xl and Mcl-1 (both are negative regulators of apoptosis) were measured ([@B15]; [@B3]). The results from western blot analysis further confirmed this assumption. As shown in [Figure 4E,F](#F4){ref-type="fig"}, Taxol treatment up-regulated the expression levels of Phospho-Histone H~2~A, and PARP, and down-regulated Bcl-Xl and Mcl-1. However, all these changes were significantly reversed by RAP treatment.

Discussion
==========

One of the main barriers in conventional anticancer therapy is its toxicity to normal tissues. Up until now, the specific clinical approaches that can be used to reduce the chemotherapy-mediated toxicities are rare. Recently, several studies have reported that herbal extracts originated from TCM could reduce chemotherapy-induced side effects ([@B6]; [@B21]). For instance, the PHY 906, which was based on the Huang Qin Tang, can reduce CPT-11 induced gastrointestinal toxicity, and this finding was further supported by a clinical trial ([@B17]; [@B20]). TCM also can be used to improve the white cell counts in women undergoing chemotherapy for ovarian cancer ([@B5]). What is more interesting in our study is that RAP is the major polysaccharide of Radix Astragali which is an edible tonic herb that can be used for a long time without any toxicity concern. Actually, Radix Astragali has been used to improve the Qi of small lung cancer patients ([@B12]). TA-65, a proprietary exact from Radix Astragali, was associated with a significant age-reversal effect ([@B19]). These studies and our results suggest that RAP has great potential in cancer therapy.

The mechanism underlying the protective effect of RAP is complicated. RAP may bind to many target molecules, then trigger subsequent signal cascades, many of which are interconnected. We used RAW 264.7 cells as a model to study the probable mechanism of the protective effect *in vitro* since the macrophage is one of the most sensitive immune cells responding to RAP and Taxol in splenocyte of mice (data not shown). In the part of cell cycle, similar to reported work ([@B47]), we found that Taxol increased the expression of cell cycle protein Chk1, while RAP decreased it to almost normal levels. In the part of signaling pathways involved in Taxol-induced cytotoxicity, involving p38, JNK, ERK ([@B8]; [@B27]), we didn't find any relationship between those signals and RAP's effect (data not shown). Instead, we found that activation of both p53 and p21 played a critical role in RAP's ability to protect normal cells from Taxol-induced apoptosis. Combination with RAP decreased the high expression of p53 and p21 induced by Taxol. Recent work by Becker et al. also showed that p53 is a key factor of Roc-A, a Chinese medicine formula which showed a protective effect against chemotherapy ([@B2]).

According to previous studies, two distinct sets of biomarkers needed to be considered in chemotherapy-induced apoptosis. One set were those controlling DNA damage-dependent post-slippage death, for example p53 and its involving genes; another set were genes that regulate cell death during prolonged mitotic arrest, such as Bcl-Xl and Mcl-1 ([@B47]). The formation of multiple small nuclei was also a marked feature of cells that slip out of Taxol-induced mitotic arrest ([@B33]; [@B47]). In our study, RAP inhibited the apoptosis of RAW 264.7 cells affected by Taxol. Less nuclear fragmentation was founded in the RAP+Taxol group, compared with Taxol alone. RAP also successfully inhibited the Taxol-induced H~2~A and PARP expression, and reversed the expression of Bcl-xl and Mcl-1. Given that RAP can reverse the changes in cell cycle and apoptosis induced by Taxol, it is reasonable to suggest that RAP may have the function, at least in part, to protect normal cells from the cytotoxicity induced by Taxol.

Normally, polysaccharides are believed to have low oral bioavailability, due to their high molecular weight and low stability in the digestive tract ([@B29]; [@B9]). Actually, some polysaccharides could be digested in gut tract, but not all. Previous studies have reported that orally administered β-1,3-glucans can be transferred to spleen lymph nodes and bone marrow with the help of macrophages ([@B10]). Because we have found that RAP showed strong immune-modulating effects on macrophages, it is also possible for RAP to directly interact with the main immune organ of the small intestine, the Peyer's patch. Another possibility has been highlighted by more and more literature addressing the importance of gut microbiota in beneficial effects of fiber diet. Like fiber, RAP possibly functions as optimum food for some specific gut bacteria, modulating the composition and function of gut microbiota which subsequently affects the health of the host body. The weakness in conventional bioavailability of RAP might not be problematic enough to weaken its clinical potential when more evidences are obtained in the future.

Conclusion
==========

The results obtained in this study indicated that RAP treatment effectively reduced the cytotoxicity induced by Taxol. It appears to work by reversing the changes in cell cycle and apoptosis that are caused by Taxol. The efficacy of the RAP-Taxol combination warrants further study.
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